Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes

Not Applicable

Completed

• Conditions: Hypertension; Type 2 Diabetes

• Registration Number: NCT00160160
• Lead Sponsor: Solvay Pharmaceuticals

Brief Summary

This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-10
• Study First Submitted: 2005-09-08
• Study First Submitted QC: 2005-09-08
• Study First Posted: 2005-09-12
• Status Verified: 2009-01
• Last Update Submitted: 2009-01-29
• Last Update Posted: 2009-01-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 440

Inclusion Criteria

• essential hypertension,
• diabetes type 2

Exclusion Criteria

• severe cardiovascular disease,
• grade 3 hypertension,
• secondary hypertension,
• abnormal liver enzymes

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Blood pressure reduction

Secondary Outcome Measures

Name	Time	Method
Comparison of responder rates

Trial Locations

Locations (63)

Site 26; 🇨🇦 Calgary, Canada

Site 27; 🇨🇦 Montreal, Canada

Site 30; 🇨🇦 Quebec, Canada

Site 31; 🇨🇦 Thornhill, Canada

Site 28; 🇨🇦 Vancouver, Canada

Site 29; 🇨🇦 Winnipeg, Canada

Site 39; 🇩🇰 Holbaek, Denmark

Site 38; 🇩🇰 Roskilde, Denmark

Site 40; 🇩🇰 Viborg, Denmark

Site 4; 🇫🇷 Anzin, France

Scroll for more (53 remaining)